Author
Listed:
- Geeta Kumari
(Guru TegBahadur Hospital, India)
- Ajay Singh
(Sri Ram MurtiSmarak Institute of Medical Sciences, India)
- Sarang Tusharbhai Mehta
(Smt. N.H.L. Municipal Medical College, India)
- Manisha Chavan
(Kakatiya Medical College, India)
Abstract
Mitochondria are referred to as the energy centers of cells, and mitochondrial DNA are known to alter the mitochondrial respiratory chain, which reduces cellular energy and causes ion-channel malfunction and neuronal cell death. As majority of the cells contain mitochondria, these disorders involve multiple systems. Since the energy requirements of different tissues vary, their vulnerability to mitochondrial dysfunction also varies in terms of threshold. This causes these disorders to appear clinically in a variety of ways and with significant phenotypic overlap. The genotypic and phenotypic definitions of some specific symptoms are, nevertheless, well established. Potentially deadly mitochondrial toxins are present in some epileptic medications and early diagnosis of the condition can help prevent serious morbidities. We describe a typical case of sodium valproate and lamotrigine-induced fast multiaxial worsening in a patient with myoclonic epilepsy with red ragged fibers (MERRF) as these drugs act as mitochondrial poisons and could prove life threatening for patients with mitochondrial diseases. When mitochondrial cocktail was introduced and the problematic medicines were removed, the symptoms were somewhat reversed. MERRF in progeny of non- consanguineous parents is a rare occurrence resulting in poor prognosis of the disease. Epileptic drugs lamotrigine and sodium valproate should be avoided as these drugs worsen myoclonus and cause mitochondrial toxicities. With knowledge of the information in this scenario, further harm to the patient can be prevented.
Suggested Citation
Geeta Kumari & Ajay Singh & Sarang Tusharbhai Mehta & Manisha Chavan, 2023.
"Progressive Myoclonic Epilepsy: A Typical Case of MERRF and the Lessons Learnt,"
European Journal of Clinical Medicine, European Open Science, vol. 4(3), pages 1-3, April.
Handle:
RePEc:epw:clinic:v:4:y:2023:i:3:id:12261
DOI: 10.24018/clinicmed.2023.4.3.261
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:clinic:v:4:y:2023:i:3:id:12261. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/clinicmed .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.